|
pubmed:abstractText |
In Japan, the standard chemotherapy for advanced transitional cell carcinoma (TCC) of the urothelium is MVAC (methotrexate, vinblastine, adriamycin, cisplatin). However, a second-line therapy is still required for patients with recurrent TCC who discontinued MVAC because of toxicity or have MVAC refractory tumors.
|
|
pubmed:affiliation |
Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan. akazah@md.tsukuba.ac.jp
|
